First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age.
J Gastrointest Oncol
; 10(5): 910-917, 2019 Oct.
Article
em En
| MEDLINE
| ID: mdl-31602329
ABSTRACT
BACKGROUND:
Nab-paclitaxel plus gemcitabine represents one of the standard regimens for first line treatment of metastatic pancreatic cancer (mPC). Few data are available on nab-paclitaxel plus gemcitabine in geriatric population. Our study aims to show whether this schedule can be feasible in the elderly as first-line treatment for mPC.METHODS:
We retrospectively analyzed the data of 64 mPC patients (≥65 years old) treated according to the MPACT schedule.RESULTS:
Median age was 69.5 years (range, 65-80 years); after a median of 5 cycles administered (range, 1-12), the most common adverse events (AEs) were grade 2 alopecia (46.9%), anemia (17.2%) and hypertransaminasemia (10.9%); all grades neutropenia occurred in 20.3% of pts. Global incidence of grade 3 and 4 toxicities were 26.5% and 0%, respectively, and no patients stopped treatment due to unacceptable toxicity. Stable disease (SD) was observed in 31.2% of patients, with a disease control rate (DCR) and overall response rate of 57.8% and 26.6%, respectively. After a median follow-up of 18 months, median progression free survival (PFS) was 8 months (95% CI 6.3-9.6) and median OS was 12.0 months (95% CI 8.4-15.6). The univariate analysis for overall survival (OS) showed that only ECOG performance status was an independent prognostic factor for survival.CONCLUSIONS:
Nab-paclitaxel plus gemcitabine schedule is feasible and effective in the "daily clinical practice" geriatric population.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
Idioma:
En
Revista:
J Gastrointest Oncol
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Itália